Evidence map›Paper›PMID 32591923›Full record

ArticleCurrent microbiology2020

In Vitro Studies on Therapeutic Potential of Probiotic Yeasts Isolated from Various Sources.

Mangala Lakshmi Ragavan, Nilanjana Das

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. In vitro characterization of probiotic properties of isolated and grown co-cultures on halophyte-based substrate.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Potential probiotic and functional properties ofFrontiers in microbiology · 2024
    Article
  7. Review
  8. Review
  9. Yarrowia lipolytica, health benefits for animals.Applied microbiology and biotechnology · 2021
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mangala Lakshmi RagavanDepartment of Biomedical Sciences, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Nilanjana DasDepartment of Biomedical Sciences, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India. nilanjanamitra@vit.ac.in.
Vellore Institute of Technology University · IN

Funding

Indian Council of Medical Research OMI- Fellowship/1/2019-ECD-1 & ID No. 2019-0420
6 · The paper itself

Abstract

The present study investigates the therapeutic properties of probiotic yeasts viz. Yarrowia lipolytica VIT-MN01, Kluyveromyces lactis VIT-MN02, Lipomyces starkeyi VIT-MN03, Saccharomycopsis fibuligera VIT-MN04 and Brettanomyces custersianus VIT-MN05. The antimutagenic activity of probiotic yeasts against the mutagens viz. Benzo[a]pyrene (B[a]P), and Sodium azide (SA) was tested. S. fibuligera VIT-MN04 showed highest antimutagenicity (75%). Binding ability on the mutagen acridine orange (AO) was tested and L. starkeyi VIT-MN03 was able to bind AO effectively (88%). The probiotic yeasts were treated with the genotoxins viz. 4-Nitroquinoline 1-Oxide (NQO) and Methylnitronitrosoguanidine (MNNG). The prominent changes in UV shift confirmed the reduction in genotoxic activity of S. fibuligera VIT-MN04 and L. starkeyi VIT-MN03, respectively. Significant viability of probiotic yeasts was noted after being exposed to mutagens and genotoxins. The adhesion capacity and anticancer activity were also assessed using Caco-2 and IEC-6 cell lines. Adhesion ability was found to be more in IEC-6 cells and remarkable antiproliferative activity was noted in Caco-2 cells compared to normal cells. Further, antagonistic activity of probiotic yeasts was investigated against S. typhimurium which was found to be more in S. fibuligera VIT-MN04 and L. starkeyi VIT-MN03. The inhibition of α-glucosidase and α-amylase activity confirmed the antidiabetic activity of probiotic yeasts. Antioxidant activity was also tested using standard assays. Therefore, based on the results, it can be concluded that probiotic yeasts can serve as potential therapeutic agents for the prevention and treatment of colon cancer, type 2 diabetes and gastrointestinal infections.

Indexed as

ProbioticsYeastsBrettanomycesCaco-2 CellsCell LineColonic NeoplasmsDiabetes Mellitus, Type 2HumansKluyveromycesLipomycesSaccharomycopsisYarrowia

Identifiers

PMID32591923
OpenAlexW3037268728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.